138 found
Order:
Disambiguations
Rebecca Dresser [136]Rebecca S. Dresser [5]
  1.  51
    Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field.Leili Fatehi, Susan M. Wolf, Jeffrey McCullough, Ralph Hall, Frances Lawrenz, Jeffrey P. Kahn, Cortney Jones, Stephen A. Campbell, Rebecca S. Dresser, Arthur G. Erdman, Christy L. Haynes, Robert A. Hoerr, Linda F. Hogle, Moira A. Keane, George Khushf, Nancy M. P. King, Efrosini Kokkoli, Gary Marchant, Andrew D. Maynard, Martin Philbert, Gurumurthy Ramachandran, Ronald A. Siegel & Samuel Wickline - 2012 - Journal of Law, Medicine and Ethics 40 (4):716-750.
    The nanomedicine field is fast evolving toward complex, “active,” and interactive formulations. Like many emerging technologies, nanomedicine raises questions of how human subjects research (HSR) should be conducted and the adequacy of current oversight, as well as how to integrate concerns over occupational, bystander, and environmental exposures. The history of oversight for HSR investigating emerging technologies is a patchwork quilt without systematic justification of when ordinary oversight for HSR is enough versus when added oversight is warranted. Nanomedicine HSR provides an (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark   9 citations  
  2.  87
    Dworkin on Dementia: Elegant Theory, Questionable Policy.Rebecca Dresser - 1995 - Hastings Center Report 25 (6):32-38.
  3.  8
    [Book Review] When Science Offers Salvation, Patient Advocacy and Research Ethics. [REVIEW]Rebecca Dresser - 2001 - Hastings Center Report 31 (6):47-48.
  4.  5
    Wanted.Rebecca Dresser - 1992 - Hastings Center Report 22 (1):24-29.
  5.  76
    Stem Cell Research as Innovation: Expanding the Ethical and Policy Conversation.Rebecca Dresser - 2010 - Journal of Law, Medicine and Ethics 38 (2):332-341.
    Research using human embryonic stem cells raises an array of complex ethical issues, including, but by no means limited to, the moral status of developing human life. Unfortunately much of the public discussion fails to take into account this complexity. Advocacy for liberal and conservative positions on human embryonic stem cell research can be simplistic and misleading. Ethical concepts such as truth-telling, scientific integrity, and social justice should be part of the debate over federal support for human embryonic stem cell (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark   8 citations  
  6.  14
    Off-Label Prescribing: A Call for Heightened Professional and Government Oversight.Rebecca Dresser & Joel Frader - 2009 - Journal of Law, Medicine and Ethics 37 (3):476-486.
    Under current U.S. law, physicians may prescribe drugs and devices in situations not covered on the label approved by the Food and Drug Administration. Those supporting this system say that requiring FDA approval for off-label uses would unnecessarily impede the delivery of benefits to patients. Patients do benefit from off-label prescribing that is supported by sound scientific and medical evidence. In the absence of such evidence, however, off-label prescribing can expose patients to risky and ineffective treatments. The medical community and (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   9 citations  
  7.  2
    First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless.Rebecca Dresser - 2009 - Journal of Law, Medicine and Ethics 37 (1):38-50.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   9 citations  
  8.  59
    Bioethics and Cancer: When the Professional Becomes Personal.Rebecca Dresser - 2011 - Hastings Center Report 41 (6):14-18.
    In 2006, I was diagnosed with cancer. This began a crash course in real-world medical ethics. Having cancer was awful, but it was instructive, too. The experience gave me a new understanding of what my profession is about. Individuals in the bioethics field often address topics related to cancer, such as medical decision-making, the patient-physician relationship, clinical trials, and access to health care. Yet few engaged in this work have lived with cancer themselves. Experience as a cancer patient or family (...)
    Direct download (8 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  9.  7
    First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless.Rebecca Dresser - 2009 - Journal of Law, Medicine and Ethics 37 (1):38-50.
    The 21st-century translational science campaign could lead to an increase in first-in-human trials. As tests of investigational interventions move from the laboratory to human research, scientists, officials, and review committees should address ongoing concerns about the ethics of FIH trials. In this article, I describe three ethical considerations relevant to all FIH trials: the requirement for adequate preclinical research; study design safeguards; and choice of subject population. I also examine specific ethical considerations relevant to the three subject populations involved in (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   8 citations  
  10.  3
    Stem Cell Research as Innovation: Expanding the Ethical and Policy Conversation.Rebecca Dresser - 2010 - Journal of Law, Medicine and Ethics 38 (2):332-341.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   7 citations  
  11.  8
    Treatment Decisions and Changing Selves.Rebecca Dresser - 2015 - Journal of Medical Ethics 41 (12):975-976.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  12.  14
    Subversive Subjects: Rule‐Breaking and Deception in Clinical Trials.Rebecca Dresser - 2013 - Journal of Law, Medicine and Ethics 41 (4):829-840.
    Research subjects do not always conform to research requirements. When their personal interests conflict with the demands of participation, some subjects surreptitiously break the rules. These subjects are subversive — they undermine the research endeavor. In rejecting the restrictions research imposes, subversive subjects diminish the value of research results. From one vantage point, subversive subjects engage in unethical behavior. They create risks to themselves and others; they also disregard ethical responsibilities to adhere to research agreements and tell the truth. At (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  13.  20
    The Ubiquity and Utility of the Therapeutic Misconception.Rebecca Dresser - 2002 - Social Philosophy and Policy 19 (2):271-294.
    The term “therapeutic misconception” was coined in 1982 by Paul Appelbaum, Loren Roth, and Charles Lidz. Appelbaum and his colleagues interviewed participants in several psychiatric studies, including a drug trial with a placebo control arm. Appelbaum's group found that many people were unaware of the differences between participating in a study and receiving treatment in the clinical setting. Rather than understanding these differences, study participants tended to believe that therapy and research were governed by the same primary goal: to advance (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark   10 citations  
  14. Off-Label Prescribing: A Call for Heightened Professional and Government Oversight.Rebecca Dresser & Joel Frader - 2009 - Journal of Law, Medicine and Ethics 37 (3):476-486.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  15.  14
    Building an Ethical Foundation for First-in-Human Nanotrials.Rebecca Dresser - 2012 - Journal of Law, Medicine and Ethics 40 (4):802-808.
    Novel nanomedical interventions require human testing to evaluate their safety and effectiveness. To establish a proper evidentiary basis for human trials, nanomedical innovations must first be subjected to animal and other laboratory testing. But it is uncertain whether the traditional laboratory approaches to safety evaluation will supply adequate information on nanotechnology risks to humans. This uncertainty, together with other features of nanomedical innovation, heightens the ethical challenges in conducting FIH nanotrials.
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  16.  2
    Building an Ethical Foundation for First-in-Human Nanotrials.Rebecca Dresser - 2012 - Journal of Law, Medicine and Ethics 40 (4):802-808.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  17. Subversive Subjects: Rule-Breaking and Deception in Clinical Trials.Rebecca Dresser - 2013 - Journal of Law, Medicine and Ethics 41 (4):829-840.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  18.  28
    Review Essay / Making Up Our Minds: Can Law Survive Cognitive Science?Rebecca Dresser - 1991 - Criminal Justice Ethics 10 (1):27-40.
    Lynne Rudder Baker, Saving Belief: A Critique of Physicalism Princeton: Princeton University Press, 1987, xii + 177 pp. Daniel C. Dennett, The Intentional Stance Cambridge: MIT Press, 1987, xi + 388 pp. Paul M. Churchland, Matter and Consciousness Cambridge: MIT Press, revised edition, 1988, xii + 184 pp.
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   13 citations  
  19.  14
    Pre-Emptive Suicide, Precedent Autonomy and Preclinical Alzheimer Disease.Rebecca Dresser - 2014 - Journal of Medical Ethics 40 (8):550-551.
    It's not unusual to hear someone say, ‘I'd rather be dead than have Alzheimer's’. In ‘Alzheimer Disease and Preemptive Suicide’,1 Dena Davis explains why this is a reasonable position. People taking this position will welcome the discovery of biomarkers permitting very early AD diagnosis, Davis suggests, for this will enable more of them to end their lives while they remain motivated and able to do so. At the same time, Davis observes, people would have less reason to resort to the (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  20.  6
    Toward a Humane Death with Dementia.Rebecca Dresser - 2014 - Hastings Center Report 44 (3):38-40.
  21.  88
    Quality of Life and Non-Treatment Decisions for Incompetent Patients: A Critique of the Orthodox Approach.Rebecca S. Dresser & John A. Robertson - 1989 - Journal of Law, Medicine and Ethics 17 (3):234-244.
  22.  22
    The Curious Case of Off-Label Use.Rebecca Dresser - 2007 - Hastings Center Report 37 (3):9-11.
  23.  19
    Quality of Life and Non-Treatment Decisions for Incompetent Patients: A Critique of the Orthodox Approach.Rebecca S. Dresser & John A. Robertson - 1989 - Journal of Law, Medicine and Ethics 17 (3):234-244.
  24.  5
    Wanted Single, White Male for Medical Research.Rebecca Dresser - 1992 - Hastings Center Report 22 (1):24.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   8 citations  
  25.  44
    Professionals, Conformity, and Conscience.Rebecca Dresser - 2005 - Hastings Center Report 35 (6):9-10.
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  26.  4
    Conceptual, Structural, and Practical Challenges to Ethical Allocation of Research Funds.Rebecca Dresser - 2018 - American Journal of Bioethics 18 (11):23-24.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  27.  3
    Research Information for Reasonable People.Rebecca Dresser - 2018 - Hastings Center Report 48 (6):3-4.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  28.  46
    Private-Sector Research Ethics: Marketing or Good Conflicts Management? The 2005 John J. Conley Lecture on Medical Ethics. [REVIEW]Rebecca Dresser - 2006 - Theoretical Medicine and Bioethics 27 (2):115-139.
    Pharmaceutical companies are major sponsors of biomedical research. Most scholars and policymakers focus their attention on government and academic oversight activities, however. In this article, I consider the role of pharmaceutical companies’ internal ethics statements in guiding decisions about corporate research and development (R&D). I review materials from drug company websites and contributions from the business and medical ethics literature that address ethical responsibilities of businesses in general and pharmaceutical companies in particular. I discuss positive and negative uses of pharmaceutical (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  29.  23
    Suicide Attempts and Treatment Refusals.Rebecca Dresser - 2010 - Hastings Center Report 40 (3):10-11.
  30. Advance Directives, Self-Determination, and Personal Identity.Rebecca Dresser - 1989 - In Chris Hackler, Ray Moseley & Dorothy E. Vawter (eds.), Advance Directives in Medicine. Praeger. pp. 155--70.
     
    Export citation  
     
    Bookmark   5 citations  
  31.  6
    Advance Directives and Discrimination Against People with Dementia.Rebecca Dresser - 2018 - Hastings Center Report 48 (4):26-27.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  32.  7
    Payments to Research Participants: The Importance of Context.Rebecca Dresser - 2001 - American Journal of Bioethics 1 (2):47.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  33.  16
    Pharmaceutical Company Gifts: From Voluntary Standards to Legal Demands.Rebecca Dresser - 2006 - Hastings Center Report 36 (3):8-9.
  34.  1
    Drug Compounding, Drug Safety, and the First Amendment.Rebecca Dresser - 2013 - Hastings Center Report 43 (2):9-10.
  35.  3
    Regulating Assisted Reproduction.Rebecca Dresser - 2000 - Hastings Center Report 30 (6):26-27.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  36.  4
    Case Study: An Alert and Incompetent Self The Irrelevance of Advance Directives.Rebecca Dresser & Alan B. Astrow - 1998 - Hastings Center Report 28 (1):28.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  37.  12
    Standards for Family Decisions: Replacing Best Interests with Harm Prevention.Rebecca Dresser - 2003 - American Journal of Bioethics 3 (2):54-55.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  38.  33
    Substituting Authenticity for Autonomy.Rebecca Dresser - 2009 - Hastings Center Report 39 (2):3-3.
  39.  2
    At Law: Regulating Assisted Reproduction.Rebecca Dresser - 2000 - Hastings Center Report 30 (6):26.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  40.  22
    Prenatal Testing and Disability: A Truce in the Culture Wars?Rebecca Dresser - 2009 - Hastings Center Report 39 (3):7-8.
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  41.  49
    Standards for Animal Research: Looking at the Middle.Rebecca Dresser - 1988 - Journal of Medicine and Philosophy 13 (2):123-143.
    Much of the public debate over laboratory animal use has focused on either the scientist's demand for absolute freedom of inquiry, or the abolitionist's demand for an end to animal use in science. Yet many recent proposals for reform seek instead to balance the interests of laboratory animals in avoiding harm against the interests of research beneficiaries in continued animal use. This essay is an analysis of the intermediate reform positions and their underlying ethical principles. Keywords: animal research, animal experimentation, (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  42.  1
    Advance Euthanasia Directives: A Controversial Case and its Ethical Implications.David Gibbes Miller, Rebecca Dresser & Scott Y. H. Kim - 2019 - Journal of Medical Ethics 45 (2):84-89.
    Authorising euthanasia and assisted suicide with advance euthanasia directives is permitted, yet debated, in the Netherlands. We focus on a recent controversial case in which a Dutch woman with Alzheimer’s disease was euthanised based on her AED. A Dutch euthanasia review committee found that the physician performing the euthanasia failed to follow due care requirements for euthanasia and assisted suicide. This case is notable because it is the first case to trigger a criminal investigation since the 2002 Dutch euthanasia law (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  43.  16
    The Limits of Apology Laws.Rebecca Dresser - 2008 - Hastings Center Report 38 (3):pp. 6-7.
    Direct download (7 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  44.  6
    Bound to Treatment: The Ulysses Contract.Rebecca Dresser - 1984 - Hastings Center Report 14 (3):13-16.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  45.  24
    A New Era in Drug Regulation?Rebecca Dresser - 2005 - Hastings Center Report 35 (3):10-11.
  46.  4
    Still Troubled: In Re Martin.Rebecca Dresser - 1996 - Hastings Center Report 26 (4):21-22.
  47.  1
    The Role of Patient Advocates and Public Representatives in Research.Rebecca Dresser - 2008 - In Ezekiel J. Emanuel (ed.), The Oxford Textbook of Clinical Research Ethics. Oxford University Press. pp. 231.
    Direct download  
     
    Export citation  
     
    Bookmark   1 citation  
  48.  4
    Investigational Drugs and the Constitution.Rebecca Dresser - 2006 - Hastings Center Report 36 (6):9-10.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  49.  12
    On Legalizing Physician‐Assisted Death for Dementia.Rebecca Dresser - 2017 - Hastings Center Report 47 (4):5-6.
    Last November, soon after Colorado became the latest state to authorize physician-assisted suicide, National Public Radio's The Diane Rehm Show devoted a segment to legalization of “physician assistance in dying,” a label that refers to both physician-assisted suicide and voluntary active euthanasia. Although the segment initially focused on PAD in the context of terminal illness in general, it wasn't long before PAD's potential application to dementia patients came up. A caller said that her mother had Alzheimer's disease and was being (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  50.  76
    Irrational Basis: The Legal Status of Medical Marijuana.Rebecca Dresser - 2009 - Hastings Center Report 39 (6):7-8.
1 — 50 / 138